Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - ertugliflozin pyroglutamic acid, quantity: 19.43 mg (equivalent: ertugliflozin, qty 15 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; magnesium stearate; microcrystalline cellulose; lactose monohydrate; titanium dioxide; hypromellose; triacetin; iron oxide red; macrogol 3350 - steglatro (ertugliflozin) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:- - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents,[see 5.1 pharmacodynamic properties, clinical trials and 4.4 special warnings and precautions for use for available data on different add-on combination therapies].

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - ertugliflozin pyroglutamic acid, quantity: 19.43 mg (equivalent: ertugliflozin, qty 15 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide red; macrogol 3350 - msd-ertugliflozin (ertugliflozin) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:- - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents,[see 5.1 pharmacodynamic properties, clinical trials and 4.4 special warnings and precautions for use for available data on different add-on combination therapies].

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - sitagliptin phosphate monohydrate, quantity: 128.5 mg (equivalent: sitagliptin, qty 100 mg); ertugliflozin pyroglutamic acid, quantity: 19.43 mg (equivalent: ertugliflozin, qty 15 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium stearylfumarate; microcrystalline cellulose; croscarmellose sodium; calcium hydrogen phosphate; carnauba wax; titanium dioxide; hypromellose; hyprolose; iron oxide yellow; iron oxide red; iron oxide black - msd-ertugliflozin-sitagliptin (ertugliflozin and sitagliptin phosphate monohydrate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and sitagliptin is appropriate. [see 5.1 pharmacodynamic properties, clinical trials, and 4.4 special warnings and precautions for use]

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - ertugliflozin pyroglutamic acid, quantity: 6.48 mg (equivalent: ertugliflozin, qty 5 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; triacetin; iron oxide red; macrogol 3350 - steglatro (ertugliflozin) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:- - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents,[see 5.1 pharmacodynamic properties, clinical trials and 4.4 special warnings and precautions for use for available data on different add-on combination therapies].

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - sitagliptin phosphate monohydrate, quantity: 128.5 mg (equivalent: sitagliptin, qty 100 mg); ertugliflozin pyroglutamic acid, quantity: 19.43 mg (equivalent: ertugliflozin, qty 15 mg) - tablet, film coated - excipient ingredients: carnauba wax; sodium stearylfumarate; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; calcium hydrogen phosphate; titanium dioxide; hypromellose; hyprolose; iron oxide yellow; iron oxide red; iron oxide black - steglujan (ertugliflozin and sitagliptin phosphate monohydrate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and sitagliptin is appropriate. [see 5.1 pharmacodynamic properties, clinical trials, and 4.4 special warnings and precautions for use]

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - ertugliflozin pidolate (unii: mlu731k321) (ertugliflozin - unii:6c282481ip), sitagliptin phosphate (unii: ts63ew8x6f) (sitagliptin - unii:qfp0p1dv7z) - ertugliflozin 5 mg - steglujan® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use - not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see warnings and precautions (5.1)]. - has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using steglujan [see warnings and precautions (5.2)] . - patients with severe renal impairment (<30 ml/min/1.73 m2 ), end-stage renal disease (esrd), or on dialysis [see warnings and precautions (5.4) and use in specific populations (8.6)] . - hypersensitivity to sitagliptin, ertugliflozin, or any excipient, in steglujan, reactions such as anaphylaxis or angioedema have occurred [see warnings and precautions (5.11) and adverse reactions (6.2)]. risk summary based on animal data showing adverse renal effects, from ertugliflozin, steglujan is

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - ertugliflozin pidolate (unii: mlu731k321) (ertugliflozin - unii:6c282481ip) - ertugliflozin 5 mg - steglatro® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use - not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see warnings and precautions (5.1)] . - hypersensitivity to ertugliflozin or any excipient in steglatro, reactions such as angioedema have occurred [see adverse reactions (6.2)]. risk summary based on animal data showing adverse renal effects, steglatro is not recommended during the second and third trimesters of pregnancy. the limited available data with steglatro in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . in animal studies, adverse renal changes were observed in rats when ertugliflozin was administered during a period of renal development corresponding to the late second and t

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - ertugliflozin pidolate (unii: mlu731k321) (ertugliflozin - unii:6c282481ip), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - ertugliflozin 2.5 mg - segluromet® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see warnings and precautions (5.2)]. - hypersensitivity to ertugliflozin, metformin, or any excipient in segluromet, reactions such as angioedema or anaphylaxis have occurred [see adverse reactions (6.2)]. - patients with severe renal impairment (egfr less than 30 ml/min/1.73 m2 ), end stage-renal disease (esrd), or on dialysis [see use in specific populations (8.6)] . - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. risk summary based on animal data showing adverse renal effects, from ertugliflozin, segluromet is not recommended during the second and third trimesters of pregnancy. published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage r

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - ertugliflozin pyroglutamic acid, quantity: 6.48 mg (equivalent: ertugliflozin, qty 5 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; triacetin; iron oxide red; macrogol 3350 - msd-ertugliflozin (ertugliflozin) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:- - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents,[see 5.1 pharmacodynamic properties, clinical trials and 4.4 special warnings and precautions for use for available data on different add-on combination therapies].

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - ertugliflozin (l-pga); metformin hydrochloride - film coated tablets - metformin hydrochloride 1000 mg; ertugliflozin (l-pga) 2.5 mg - metformin and ertugliflozin - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:• in patients not adequately controlled on their maximally tolerated dose of metformin alone• in patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetes • in patients already being treated with the combination of ertugliflozin and metformin as separate tablets.